RGNX

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN – Research Report), Adaptimmune Therapeutics (ADAP – Research Report) and RegenXBio (RGNX – Research Report). Illumina (ILMN) In a report released today, Puneet Souda from SVB Securities upgraded Illumina to Buy, with a price target of $270.00. The company's shares closed last Monday at $187.24, close to its 52-week low of $173.45. According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.2% and a 39.0% success rate.
https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-illumina-ilmn-adaptimmune-therapeutics-adap-and-regenxbio-rgnx?utm_source=advfn.com&utm_medium=referral